Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02083835Recruiting

PAIN OUT: Improvement in Postoperative PAIN OUTcome

Role: collaborator

NCT06878027Recruiting

Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool

Role: collaborator

NCT01784549Phase 2Unknown

Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease

Role: collaborator

NCT01946932Not ApplicableCompleted

Cognitive Impairment Following Cardiac Arrest and Target Temperature Management

Role: collaborator

NCT01041768Not ApplicableUnknown

Multicentric Prospective Randomized Trial on Surgery Versus Standard Medical Care in Type 2 Diabetic Patients BMI 30-35

Role: collaborator

All 5 trials loaded